World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
53
Citations
12892
World Ranking
3950
National Ranking
1808

James G. Kublin publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where James G. Kublin sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 217 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

James G. Kublin D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where James G. Kublin sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 53 D-Index — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

James G. Kublin is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their research primarily focuses on medicine and immunology and microbiology, with significant contributions to the fields of infectious diseases, virology, immunology, health, and epidemiology.

The scientist's work extensively covers topics related to SARS-CoV-2 and COVID-19 research, HIV research and treatment, COVID-19 clinical research studies, vaccine coverage and hesitancy, HIV/AIDS research and interventions, vaccines and immunoinformatics approaches, as well as malaria research and control.

Key recent publications include:

  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial, 2022, Science
  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition, 2021, New England Journal of Medicine
  • Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults, 2021, New England Journal of Medicine
  • Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial, 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment, 2021, PLoS ONE

Frequent co-authors in their body of work include Lawrence Corey, Peter B. Gilbert, Glenda Gray, Yunda Huang, and Lindsey R. Baden.

The most common publication venues where their research appears are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries
  • The Journal of Infectious Diseases
  • Nature Communications
  • Clinical Infectious Diseases

The scientific contributions of James G. Kublin are concentrated in studies that intersect clinical research and vaccine development, particularly involving HIV and COVID-19. The research covers vaccine efficacy trials, immune response correlates, and strategies to increase diversity in clinical trial participation.

Best Publications

  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

    Peter B Gilbert;Peter B Gilbert;David C Montefiori;Adrian B McDermott;Youyi Fong

  • Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Scott M. Hammer;Magdalena E. Sobieszczyk;Holly Janes;Shelly T. Karuna

  • Molecular Markers for Failure of Sulfadoxine-Pyrimethamine and Chlorproguanil-Dapsone Treatment of Plasmodium falciparum Malaria

    James G. Kublin;Fraction K. Dzinjalamala;Deborah D. Kamwendo;Elissa M. Malkin

  • Reemergence of Chloroquine-Sensitive Plasmodium falciparum Malaria after Cessation of Chloroquine Use in Malawi

    James G Kublin;Joseph F Cortese;Eric Mbindo Njunju;Rabia A G. Mukadam

  • Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa.

    Laith J. Abu-Raddad;Laith J. Abu-Raddad;Padmaja Patnaik;James G. Kublin;James G. Kublin

  • Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what next?

    Carol Hopkins Sibley;John E Hyde;Paul F.G Sims;Christopher V Plowe

  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

    Lawrence Corey;Peter B Gilbert;Michal Juraska;David C Montefiori

  • Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

    Glenda E. Gray;Mary. Allen;Zoe. Moodie;Gavin J. Churchyard

  • Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study

    James G Kublin;Padmaja Patnaik;Charles S Jere;William C Miller

  • Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

    Frances H. Priddy;Deborah Brown;James Kublin;Kathleen Monahan

  • Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

    Spyros A. Kalams;Scott D. Parker;Marnie Elizaga;Barbara Metch

  • Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

    Glenda E. Gray;Glenda E. Gray;Glenda E. Gray;Linda Gail Bekker;Fatima Laher;Mookho Malahleha

  • Effects of HIV-1 Serostatus, HIV-1 RNA Concentration, and CD4 Cell Count on the Incidence of Malaria Infection in a Cohort of Adults in Rural Malawi

    Padmaja Patnaik;Charles S. Jere;William C. Miller;Irving F. Hoffman

  • Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

    Nicole Frahm;Allan C. DeCamp;David P. Friedrich;Donald K. Carter

  • Tuberculosis Vaccines and Prevention of Infection

    Thomas R. Hawn;Tracey A. Day;Thomas J. Scriba;Mark Hatherill

  • Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization

    Cecilia Rademeyer;Bette Korber;Michael S Seaman;Elena E Giorgi

  • Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

    Glenda E. Gray;Glenda E. Gray;Zoe Moodie;Barbara Metch;Peter B. Gilbert

  • Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial.

    A Alloueche;W Bailey;S Barton;J Bwika

  • Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

    Unknown

  • Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study

    Christopher V Plowe;James G Kublin;Fraction K Dzinjalamala;Deborah S Kamwendo

  • Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

    Peter B. Gilbert;David C. Montefiori;David C. Montefiori;Adrian McDermott;Youyi Fong

Frequent Co-Authors

Glenda Gray
Glenda Gray South African Medical Research Council
Lawrence Corey
Lawrence Corey Fred Hutchinson Cancer Research Center
Peter B. Gilbert
Peter B. Gilbert Fred Hutchinson Cancer Research Center
M. Juliana McElrath
M. Juliana McElrath University of Washington
Linda-Gail Bekker
Linda-Gail Bekker University of Cape Town
David C. Montefiori
David C. Montefiori Duke University
Georgia D. Tomaras
Georgia D. Tomaras Duke University
Gavin J. Churchyard
Gavin J. Churchyard Aurum Institute
Nicole Frahm
Nicole Frahm Fred Hutchinson Cancer Research Center
Koleka Mlisana
Koleka Mlisana National Health Laboratory Service

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can open up diverse career opportunities in healthcare and research. Nursing programs, particularly those with more accessible admission criteria, provide a practical pathway for gaining clinical experience. Prospective students might consider lpn programs with easiest admission requirements, which offer a solid foundation for patient care roles.

Nurse Practitioner (NP) programs are another excellent route, especially for those aiming to specialize in advanced clinical roles. Programs recognized as easiest np programs to get into can be ideal for learners seeking flexible and accessible options without compromising quality.

Mental health is a growing field closely linked to immunological research and health outcomes. Online PMHNP (Psychiatric Mental Health Nurse Practitioner) programs with high success in clinical training placements can greatly enhance practical experience. Exploring pmhnp programs online with best clinical placement helps ensure hands-on learning that is crucial for this specialty.

Budget considerations are also important when selecting a program. Investigating cheapest psych np programs online offers affordable pathways to enter psychiatric nursing, which complements immunology careers focused on neuroimmune interactions.

Best Scientists Citing James G. Kublin

Trending Scientists

Recently Published Articles